Baillie Gifford & Co. Acquires New Position in Orchard Therapeutics PLC – (ORTX)

Baillie Gifford & Co. acquired a new position in Orchard Therapeutics PLC – (NASDAQ:ORTX) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 925,000 shares of the company’s stock, valued at approximately $14,550,000. Baillie Gifford & Co. owned about 1.10% of Orchard Therapeutics as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Victory Capital Management Inc. purchased a new stake in shares of Orchard Therapeutics in the fourth quarter worth approximately $106,000. Northern Trust Corp purchased a new stake in shares of Orchard Therapeutics in the fourth quarter worth approximately $579,000. Dean Capital Investments Management LLC purchased a new stake in shares of Orchard Therapeutics in the fourth quarter worth approximately $674,000. Massachusetts Financial Services Co. MA purchased a new stake in shares of Orchard Therapeutics in the fourth quarter worth approximately $6,948,000. Finally, Foresite Capital Management IV LLC purchased a new stake in shares of Orchard Therapeutics in the fourth quarter worth approximately $10,513,000. 57.82% of the stock is owned by hedge funds and other institutional investors.

Several analysts have recently commented on the company. Wedbush assumed coverage on Orchard Therapeutics in a research note on Monday, November 26th. They issued an “outperform” rating and a $25.00 price objective for the company. JPMorgan Chase & Co. assumed coverage on Orchard Therapeutics in a research note on Monday, November 26th. They issued an “overweight” rating and a $25.00 price objective for the company. Goldman Sachs Group assumed coverage on Orchard Therapeutics in a research note on Monday, November 26th. They issued a “neutral” rating and a $18.00 price objective for the company. Cowen assumed coverage on Orchard Therapeutics in a report on Monday, November 26th. They issued an “outperform” rating and a $27.00 target price for the company. Finally, ValuEngine lowered Orchard Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 21st. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $22.45.

ORTX stock opened at $14.90 on Friday. Orchard Therapeutics PLC – has a 12-month low of $8.65 and a 12-month high of $19.24.

COPYRIGHT VIOLATION WARNING: This article was originally reported by WKRB News and is the sole property of of WKRB News. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at https://www.wkrb13.com/2019/03/15/baillie-gifford-co-acquires-new-position-in-orchard-therapeutics-plc-ortx.html.

About Orchard Therapeutics

Orchard Therapeutics plc, integrated biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified drug product to treat the patient's disease through a single administration.

Further Reading: What is a put option?

Want to see what other hedge funds are holding ORTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Orchard Therapeutics PLC – (NASDAQ:ORTX).

Institutional Ownership by Quarter for Orchard Therapeutics (NASDAQ:ORTX)

Receive News & Ratings for Orchard Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchard Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.